Germany · Delayed Price · Currency is EUR KalVista Pharmaceuticals Company Description
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.
The company’s product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks.
KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 270 |
| CEO | Benjamin Palleiko |
Contact Details
Address: 55 Cambridge Parkway Cambridge, Delaware 02142 United States | |
| Phone | 857 999 0075 |
| Website | kalvista.com |
Stock Details
| Ticker Symbol | 4XC1 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Benjamin Palleiko | Chief Executive Officer |
| Brian Piekos | Chief Financial Officer |
| Bilal Arif | Chief Operating Officer |
| Ryan Baker | Head of Investor Relations |